Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00985127 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
A Phase 2 study of Gout, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 20
- Study locations
NCT00985127: Completed Phase 2 study of Gout, sponsored by BioCryst Pharmaceuticals.
NCT00985127 is a Phase 2 study of Gout that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 99 participants, below the 8,885-participant average among 34 other Gout trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00985127, a Phase 2 study of Gout, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will be conducted in two parts. The first is a parallel-group design, evaluating doses of 40 mg, 80 mg or 120 mg BCX-4208. The second part is planned as a dose-escalation study, evaluating higher doses including 160 mg, 240 mg and 320 mg BCX-4208. The study's primary endpoint is the change in uric acid in the blood compared to baseline measurement prior to treatment, assessed on Day 22.
Conditions Studied
Interventions
- DRUG placebo
- DRUG BCX4208
Study Locations (20)
Arizona
- Radiant Research, Inc. - Scottsdale
- Catalina Pointe Clinical Research - Tucson
California
- Irvine Center for Clinical Research - Irvine
- San Diego Arthritis Medical Clinic - San Diego
Florida
- Avail Clinical Research - DeLand
- Anchor Research Center - Naples
Hawaii
- East-West Medical Research Institute - Honolulu
Idaho
- Selah Medical Center - Boise
Kentucky
- Kentucky Medical Research Center - Lexington
Maryland
- Arthritis & Osteoporosis Center of Maryland - Frederick
Mississippi
- Olive Branch Family Medical Center - Olive Branch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
What the finished NCT00985127 record still lists
NCT00985127 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 8,885-participant average among 34 other Gout trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Gout appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00985127 names 20 study sites across 17 states, led by Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00985127 about?
NCT00985127 is a clinical study titled "Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout". The study will be conducted in two parts. The first is a parallel-group design, evaluating doses of 40 mg, 80 mg or 120 mg BCX-4208. The second part is planned as a dose-escalation study, evaluating higher doses including 160 mg, 240 mg and 320 mg BCX-4208. The study's primary endpoint is the change...
What is the current status of trial NCT00985127?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2009-09. Estimated completion is 2010-09.
What conditions does trial NCT00985127 study?
This clinical trial studies the following conditions: Gout.
What interventions are being tested in trial NCT00985127?
The interventions under investigation include: placebo (DRUG), BCX4208 (DRUG).
Who is sponsoring clinical trial NCT00985127?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00985127 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Hawaii, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00985127's enrollment target sits among peer trials
99 17th of 34 higher than 18 of 34 other Gout trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gout trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
RECRUITING · Phase 2
-
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
RECRUITING · Phase 2
-
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
ACTIVE NOT RECRUITING · Phase 2
-
Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.
ACTIVE NOT RECRUITING · Phase 2
-
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia